GroPep Limited
28 Dalgleish Street
Thebarton
South Australia
5031
Tel: 61-8-8354-7700
Fax: 61-8-8354-7788
Website: http://www.gropep.com.au/
About GroPep Limited
GroPep Limited is a biopharmaceutical company that develops, manufactures and commercialises products that bring significant benefits to human health. GroPep listed on the Australian Stock Exchange in 2000. Our 80 staff are based at modern, purpose built facilities in Adelaide, South Australia. The Company is a globally orientated business with exports contributing 95% of sales revenue and 72% of total revenue. GroPep operates two related business activities:1) Biopharmaceutical Drug Development GroPep's strategy is to in-license preclinical projects and develop them from pre-clinical proof-of-concept through phase 2 trials. During clinical development, GroPep will partner with branded pharmaceutical companies to complete clinical development. Currently there are 5 products in clinical development, 4 of which are available for licensing.
GroPep is currently seeking new in-licensing opportunities to maintain its pipeline. Our core technical competencies are:
2) Biological Products GroPep develops, manufactures and markets growth factors for use in pharmaceutical cell culture. Our leading product, LongTMR3IGF-I, is marketed and distributed by JRH Biosciences Inc, a subsidiary of CSL Limited. Three US FDA approved pharmaceuticals are manufactured using GroPep growth factors, with a number of other potential pharmaceuticals in development using GroPep growth factors. GroPep also sells growth factors and associated reagents to university, institutional and industrial researchers.
Highlights
Last Updated: 05-27-04